Anthracycline

A small study showed no impact from troponin-guided carvedilol and candesartan intervention to preserve cardiac function among seemingly high-risk patients undergoing chemotherapy.

Treatment with anthracyclines for breast cancer or lymphoma correlated with more than two times higher risk for congestive heart failure than that of healthy controls, according to a study conducted at Mayo Clinic.

Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.

NEW ORLEANS — Reduced left ventricular ejection fraction may be tied to adverse changes in muscle quality among patients with breast cancer or lymphoma undergoing cancer treatment with anthracyclines, a speaker reported.

The European Society of Cardiology task force on cardio-oncology has issued its inaugural guideline for the prevention and management of cardiotoxicity before, during and after adult patients are treated with anticancer therapies.

Long-term CV effects of cancer and its associated therapies.

In patients with diabetes and cancer treated with anthracyclines, SGLT2 inhibition was associated with fewer cardiac events during 1.5 years of follow-up, researchers reported.

Adult survivors of childhood cancer were more likely be undertreated for CVD risk factors, particularly hypertension and dyslipidemia, compared with controls, according to data published in the Journal of the American Heart Association.

Genetic variants of the UACA gene, a critical regulator of tumor suppressor Par-4, appeared associated with OS among patients who received anthracyclines and HER2-targeted therapy, according to a study published in NPJ Breast Cancer.

Women with breast cancer exhibited higher risk for heart failure, cardiomyopathy and other cardiovascular disease events than women without breast cancer, according to prospective study results published in Journal of Clinical Oncology.